Most patent enforcement stories start with a headline: a big win, a major settlement, a court victory.
But the most valuable outcomes often happen quietlybefore a full infringement case ever reaches a final judgment.
The article on DrugPatentWatchSue…

The 180-day exclusivity trap: why first-to-file winners still lose money
In pharma, we tell a comforting story: file first, win exclusivity, collect the payoff.
But the realityespecially for ANDA and 505(b)(2) follow-on strategiesis messier. The 180-da…

Most wins in pharma patent litigation arent wins at all. Theyre schedulesdelays disguised as strategy.
Heres the uncomfortable truth: if you treat a drug patent settlement as your default playbook, you may be paying real money for a solution thats only…

Drug patents are supposed to be fortresses. But the first crack usually isnt at the strongest wallits at the weakest one.
In the classic story, patents fail because the science moves faster than the claims. In practice, they often fail because enforcem…

Most new drug patents dont create new drugs. They create new barriers.
The pharmaceutical patent system is often described as a balance: enough protection to reward innovation, enough freedom to let patients access medicines sooner. But in practice, a …

Pediatric exclusivity was supposed to be a shield. In practice, its too often a fuseburning value, delaying competition, and reshaping incentives in ways policymakers didnt fully anticipate.
When people hear pediatric exclusivity, they tend to think …

Bausch Healths recent patent battle with Sun Pharma isnt just another courtroom updateits a playbook for how the next phase of branded-drug value will be defended.
And the market is already reacting.
Heres the core point: when generics and biosimilars …

Agitation: Patent battles are often framed as technical footnotesclaim charts, priority dates, likelihood of infringement. But for pharma companies, these disputes decide something much more immediate: who gets to sell a medicine, when, and at what pri…

🚨 The next pay-for-delay fight may not be where you expect itit’s in the fine print of patent strategy.
Amneal Pharmaceuticals v. Alembic Pharmaceuticals (DrugPatentWatch) is a reminder that generics arent just racing on sciencetheyre racing on IP t…

Exelixis v. Handa: The Patent Courtship That Could Reshape Pipeline Value
Agitation: Investors often assume patent litigation is just legal noisea delay tactic, a headline, another quarterly risk factor. But when the dispute centers on core IP, the out…